• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Emergent BioSolutions Inc.

    4/16/26 9:30:39 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email
    DEFA14A 1 d110931ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Emergent BioSolutions Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    On April 16, 2026, Emergent BioSolutions Inc. sent the following message to its employees.

    Annual Meeting of Stockholders Coming Up, A Reminder to Vote

     

    LOGO

    The 2026 annual meeting of Emergent stockholders will be April 29, 9 a.m. Eastern Time.

    The big picture: If you are an eligible shareholder (vested shares as of March 6, 2026), be sure to vote.

     

      •  

    Even if you can’t attend the virtual meeting, you can still vote by proxy.

    What’s next: Look for an E*TRADE email with details on how to vote.

     

      •  

    Search your inbox for the email from [email protected].

    If you’re having trouble with account access, contact customer service.

    Get the next $EBS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Williams Paul Anthony

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    4/3/26 4:05:55 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Financial Officer Lindahl Richard S

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    3/6/26 8:50:53 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Papa Joseph C covered exercise/tax liability with 37,055 shares, decreasing direct ownership by 11% to 305,445 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    3/5/26 9:40:29 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    5/15/25 4:02:40 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    SEC Filings

    View All

    SEC Form DEFA14A filed by Emergent BioSolutions Inc.

    DEFA14A - Emergent BioSolutions Inc. (0001367644) (Filer)

    4/16/26 9:32:49 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Emergent BioSolutions Inc.

    DEFA14A - Emergent BioSolutions Inc. (0001367644) (Filer)

    4/16/26 9:30:39 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Emergent BioSolutions Inc.

    SCHEDULE 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    4/9/26 1:42:19 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

    GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company has closed on a new credit facility agreement with OrbiMed for a new $150 million term loan. The proceeds from the new Term Loan were used to repay all amounts outstanding under the previous Term Loan facility agreement with Oak Hill Advisors. Emergent also amended its asset-based revolving loan facility (ABL) with Wells Fargo National Association, which now provides borrowing capacity of up to $50 million. Both the new Term Loan agreement and the ABL amendment extend maturities up to five years, through April 2031. "We continue to push forward in strengthening our

    4/16/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

    GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can b

    4/16/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

    WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE:EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province's Take-Home Naloxone Program (BC THN Program). This order follows an additional investment of $18 million CAD by the B.C. government to expand the BC THN Program to include nasal naloxone. This is an expansion of B.C.'s nasal naloxone pilot program, which launched in 2024, and provided 60,000 nasal naloxone kits to community sites, pharmacies, post-secondary institutions, First-Nations-mandated institutions, fire departments, municipalities and libraries. "We ap

    4/9/26 4:25:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

    H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

    12/30/24 7:24:57 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

    Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

    8/22/24 7:22:39 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

    3/7/24 10:14:18 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Leadership Updates

    Live Leadership Updates

    View All

    Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

    GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. "We're pleased to welcome John to the board of directors at this important point in the company's ongoing turnaround and transformation," said Dr. Zsolt Harsanyi, Ph.D., chairman of the board. "John's deep experience in healthcare and financial markets will provide valuable insight as the company continues to execute against i

    3/3/26 8:00:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

    GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) announced today that Dr. Louis W. Sullivan will retire from the company's Board of Directors effective November 14 after 19 years of service to the company and its shareholders. "For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent's mission to protect and save lives," said Joe Papa, president and CEO of Emergent. "On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best." Dr. Sullivan served on Emergent's Board of Directors since 2006, and most recently served as chair of the

    11/12/25 4:01:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

    Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an

    11/4/24 7:30:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Financials

    Live finance-specific insights

    View All

    Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

    GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can b

    4/16/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of

    2/26/26 4:05:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of

    2/12/26 9:02:20 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Emergent BioSolutions Inc.

    SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/13/24 4:00:18 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    11/8/24 5:23:28 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Emergent BioSolutions Inc.

    SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)

    9/10/24 12:09:00 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care